Related Experiment Video
Updated: Jan 22, 2026

Author Spotlight: A Cost-Effective Genomic Workflow for Advancing Rabies Control in Resource-Limited Settings
Published on: August 18, 2023
Sequencing and analysis of globally obtained human parainfluenza viruses 1 and 3 genomes
Michael E Bose1, Susmita Shrivastava2, Jie He1
1Midwest Respiratory Virus Program, Medical College of Wisconsin, Milwaukee, WI, United States of America.
Insights
Human Parainfluenza viruses (HPIV) types 1 and 3 cause widespread childhood respiratory infections. This study sequenced HPIV genomes globally, revealing diverse circulating lineages and informing future prevention strategies.
Area of Science:
- Virology
- Epidemiology
- Genetics
Background:
- Human Parainfluenza viruses (HPIV) types 1 and 3 are significant global causes of respiratory illness in young children.
- Incomplete immunity leads to recurrent HPIV infections throughout life.
- The lack of an effective vaccine necessitates a deeper understanding of HPIV-1 and HPIV-3 genetic and epidemic characteristics.
Purpose of the Study:
- To generate whole-genome sequences for HPIV-1 and HPIV-3 from diverse global locations.
- To enhance understanding of the global genetic diversity of HPIV at the whole-genome level.
- To provide data crucial for the diagnosis, prevention, and treatment of HPIV infections.
Main Methods:
- Collected HPIV-1 and HPIV-3 samples from seven countries between 2003-2011.
- Sequenced the genomes of 40 HPIV-1 and 75 HPIV-3 viruses.
- Utilized both Sanger and next-generation sequencing technologies (Ion Torrent, Illumina, 454 platforms).
Main Results:
- Phylogenetic analysis revealed distinct lineages of both HPIV-1 and HPIV-3 circulating globally.
- Estimated the evolutionary rate for HPIV-1 at 4.97 × 10⁻⁴ mutations/site/year.
- Estimated the evolutionary rate for HPIV-3 at 3.59 × 10⁻⁴ mutations/site/year.
Conclusions:
- Multiple genetically distinct lineages of HPIV-1 and HPIV-3 exist worldwide.
- Continuous surveillance and whole-genome sequencing are essential for understanding the global spread of these viruses.
- This research contributes vital data for developing effective HPIV control measures.
Abstract:
Human Parainfluenza viruses (HPIV) type 1 and 3 are important causes of respiratory tract infections in young children globally. HPIV infections do not confer complete protective immunity so reinfections occur throughout life. Since no effective vaccine is available for the two virus subtypes, comprehensive understanding of HPIV-1 and HPIV-3 genetic and epidemic features is important for diagnosis, prevention, and treatment of HPIV-1 and HPIV-3 infections. Relatively few whole genome sequences are available for both HPIV-1 and HPIV-3 viruses, so our study sought to provide whole genome sequences from multiple countries to further the understanding of the global diversity of HPIV at a whole-genome level. We collected HPIV-1 and HPIV-3 samples and isolates from Argentina, Australia, France, Mexico, South Africa, Switzerland, and USA from the years 2003-2011 and sequenced the genomes of 40 HPIV-1 and 75 HPIV-3 viruses with Sanger and next-generation sequencing with the Ion Torrent, Illumina, and 454 platforms. Phylogenetic analysis showed that the HPIV-1 genome is evolving at an estimated rate of 4.97 × 10-4 mutations/site/year (95% highest posterior density 4.55 × 10-4 to 5.38 × 10-4) and the HPIV-3 genome is evolving at a similar rate (3.59 × 10-4 mutations/site/year, 95% highest posterior density 3.26 × 10-4 to 3.94 × 10-4). There were multiple genetically distinct lineages of both HPIV-1 and 3 circulating on a global scale. Further surveillance and whole-genome sequencing are greatly needed to better understand the spatial dynamics of these important respiratory viruses in humans.
Related Concept Videos
Viruses with RNA Genomes
Genomics
Global Climate Change
What are Viruses?
Genome Size and the Evolution of New Genes
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...

